Safety profile established over more than 2 years1

Chart displaying adverse reactions in ≥ 10% patients with dMMR Endometrial Cancer who Received JEMPERLI (dostarlimab-gxly) in GARNET

Toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.


Intent-to-treat population (N=150).

Includes fatigue and asthenia.

Includes anemia, decreased hemoglobin, iron deficiency, and iron deficiency anemia.


Includes rash, rash maculo-papular, rash pruritic, erythema, and pemphigoid.

Includes increased alanine aminotransferase, increased aspartate aminotransferase, increased transaminases, and hypertransaminasemia.


dMMR=mismatch repair deficient.

Icon: 10%

of patients permanently discontinued therapy due to adverse reactions1

Icon: 10%

of patients permanently discontinued therapy due to adverse reactions1

  • Adverse reactions leading to discontinuation were increased transaminases, sepsis, bronchitis, pneumonitis, rash, pruritus, pancreatitis, encephalitis, and nephritis (15 patients total)1
  • The most common adverse reactions (≥20%) were fatigue/asthenia, anemia, rash, nausea, diarrhea, constipation and vomiting1
  • Serious adverse reactions occurred in 38% of patients receiving JEMPERLI, including (>2% of patients) urinary tract infection (4%), sepsis (3.3%), acute kidney injury (2.7%), and abdominal pain (2.7%)1
  • A fatal adverse reaction occurred in one patient (0.7%) who received JEMPERLI, due to concurrent immune-mediated encephalitis and urinary tract infection1
Icon: JEMPERLI (dostarlimab-gxly) Dosing and Administration

Find out how to dose and
administer JEMPERLI.

Icon: JEMPERLI (dostarlimab-gxly) Support

Get support for
JEMPERLI at every step.

Icon: JEMPERLI (dostarlimab-gxly) Trial

Explore the pivotal trial